Kymera Therapeutics Inc (KYMR) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.
Over the past 4 years, Kymera Therapeutics Inc has achieved a revenue compound annual growth rate (CAGR) of 8.4%, while earnings have grown at 48.9% CAGR.
Historical revenue and profitability trends for Kymera Therapeutics Inc
The chart above illustrates Kymera Therapeutics Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Kymera Therapeutics Inc's business.
How efficiently Kymera Therapeutics Inc converts revenue into profit
Profit margins reveal how much of each dollar of revenue Kymera Therapeutics Inc retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Kymera Therapeutics Inc to continue focusing on sustainable operations. The consensus analyst rating is 4.55 based on 20 analysts.
Based on our comprehensive analysis, Kymera Therapeutics Inc (KYMR) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Kymera Therapeutics Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Kymera Therapeutics Inc stacks up against similar companies
Explore growth analysis for top stocks
Related: KYMR Valuation, KYMR Dividend, KYMR Financial Health
Compare: KYMR vs AAPL, KYMR vs MSFT, KYMR vs GOOGL